BALTIMORE, Sept. 18,
2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc.
(NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage
pharmaceutical company focused on the development and
commercialization of a novel synthetic THC analog named MIRA1a,
explored the scientific and social drivers behind its development
of MIRA1a today at the Cannabinoid Derived Drug Development Summit.
The Company shared data and research that positions MIRA1a as a
potential future alternative prescription medication with unique
properties not found in THC as well as the potential for fewer side
effects.
As an invited speaker at the 6th Annual Cannabinoid
Derived Drug Development Summit held in Boston, Dr. Adam
Kaplin, President and Chief Scientific Officer of MIRA
Pharmaceuticals, said that Mira1a is a new molecular entity that in
pre-clinical studies enhances cognitive performance and diminishes
anxiety, while potentially aiding models of neuropathic pain.
"Because marijuana often impairs cognition, it can worsen
performance in school or at work and make it dangerous to drive,"
said Dr. Kaplin. "Research and studies have also linked heavy
marijuana use in children and adolescents to declines in IQ, and in
adults has negative effects on attention, memory, and learning.
With one molecular change from THC to Mira1a, we now have an
opportunity to have a substantial impact on the future of
cannabinoids in healthcare and disease."
Dr. Kaplin, previously the Chief Neuropsychiatric Consultant to
the Johns Hopkins MS Center of Excellence and the founding Director
of the Johns Hopkins Ketamine Clinic, was invited to share the
latest pre-clinical research on mice. The results showed that when
given MIRA1a, mice doubled their cognitive performance.
"Healthcare professionals are increasingly turning to marijuana
for the benefits it can provide patients, but for a significant
number of patients, the unwanted side effects continue to remove it
as a viable option," added Erez
Aminov, the Chief Executive Officer of Mira
Pharmaceuticals.
For more information, please reference MIRA's publication,
Getting into the weeds on cannabis: Known potential side-effects
and toxicity, available on the Company's website at
https://www.mirapharmaceuticals.com/mira1a.
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a
pre-clinical-stage pharmaceutical development company developing an
unscheduled novel synthetic THC analog. This novel compound is
currently under investigation for potentially treating adults
suffering from anxiety and cognitive decline, often associated with
early-stage dementia. MIRA1a, if approved by the FDA, could mark a
significant advancement in addressing various neuropsychiatric,
inflammatory, and neurologic diseases and disorders. Based on
pre-clinical studies conducted on behalf of the Company, the
Company believes that MIRA1a may enhance the therapeutic potential
for treating anxiety, cognitive decline, and neuropathic pain with
potentially fewer side effects than THC. Furthermore, the Company's
studies indicate that MIRA1a, rather than impairing cognition like
THC, produces enhanced cognitive performance.
The U.S. Drug Enforcement Administration (DEA)'s scientific
review of MIRA1a concluded that MIRA1a is not considered a
controlled substance or listed chemical under the Controlled
Substances Act (CSA) and its governing regulations.
Additional information about the Company is available
at: www.mirapharmaceuticals.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
the Company's current expectations. These forward-looking
statements include, without limitation, references to the Company's
expectations regarding the closing of the public offering and its
anticipated use of net proceeds from the offering. These statements
are not guarantees of future performance and are subject to certain
risks, uncertainties and assumptions that are difficult to predict.
Factors that could cause actual results to differ include, but are
not limited to, risks and uncertainties related to the satisfaction
of customary closing conditions related to the public offering, or
factors that result in changes to the Company's anticipated use of
proceeds. These and other risks and uncertainties are described
more fully in the section captioned "Risk Factors" in the Company's
Registration Statement on Form S-1, as amended, related to the
public offering (SEC File No. File No. 333-273074). Forward-looking
statements contained in this announcement are made as of this date,
and the Company undertakes no duty to update such information
except as required under applicable law.
View original
content:https://www.prnewswire.com/news-releases/mira-pharmaceuticals-shows-its-prescription-pill-more-palatable-and-potent-than-pot-301929929.html
SOURCE MIRA Pharmaceuticals, Inc.